Skip to main content

Abbott to Develop Companion Dx for Epizyme Cancer Drug Candidate

NEW YORK (GenomeWeb News) – Epizyme today said that Abbott will develop a molecular companion diagnostic test for a leukemia drug candidate that the Cambridge, Mass.-based firm is developing.

Abbott will develop a test based on its fluorescence in situ hybridization technology to detect genetic alterations of mixed lineage leukemia, an aggressive subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Epizyme is developing an inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia and will use the Abbott test to detect MLL genetic alterations that lead to the oncogenic function of DOT1L.

Further terms of the alliance were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.